ECM
TARS icon

Endurant Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Endurant Capital Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-47,649
Closed -$847K – 49
2023
Q3 		$847K Buy
+47,649
New +$843K 0.76% 31
2021
Q2 		– Sell
-14,143
Closed -$456K – 78
2021
Q1 		$456K Buy
+14,143
New +$523K 0.12% 60

Other funds holding TARS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Endurant Capital Management's TARS Position: Q4 2023 in Review

Endurant Capital Management sold out of Tarsus Pharmaceuticals (TARS) in Q4 2023, closing a stake of 47,649 shares — an estimated $847K sold.

Endurant Capital Management first reported a position in TARS in Q1 2021 and held it in 2 quarters. The position peaked at $847K in Q3 2023. 116 funds tracked by Wall St. Rank hold TARS as of Q4 2023.

  • Endurant Capital Management reported no remaining Tarsus Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Endurant Capital Management sold 47,649 Tarsus Pharmaceuticals shares in Q4 2023, an estimated $847K.
  • Endurant Capital Management first reported a position in Tarsus Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Endurant Capital Management's Tarsus Pharmaceuticals position peaked at $847K in Q3 2023.
  • 116 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q4 2023.

Based on Endurant Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.